Skip to main content
Philip Kantoff, MD, Oncology, New York, NY

PhilipWKantoffMD

Oncology • New York, NY

Hematologic Oncology

CEO and Co-Founder, Convergent Therapeutics

Join to view full profile

Dr. Kantoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kantoff's full profile

Already have an account?

  • Office

    Memorial Sloan Kettering Cancer Center New York
    1275 York Avenue
    New York, NY 10021

Summary

  • Dr. Philip Kantoff is the CEO and Co-Founder of Convergent Therapeutics in Cambridge, Massachusetts. He is a medical oncologist and former Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is also the Jerome and Nancy Kohlberg Chair Emeritus at Harvard Medical School. He received his medical degree from The Warren Alpert Medical School of Brown University, his residency at NYU-Bellevue in New York and his fellowship in medical oncology at the Dana-Farber Cancer Institute.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1989
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1979 - 1983
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 1979

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1987 - 2025
  • NY State Medical License
    NY State Medical License 1979 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • Boston Magazine Castle Connolly, 2008-2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Association of Genetic Variation of the Six Gene Prognostic Model for Castration‐Resistant Prostate Cancer with Survival  
    Mark M Pomerantz, Philip W Kantoff, The Prostate
  • A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer  
    Christopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate

Lectures

  • 16th Biennial Urologic Cancer Course 
    Harvard Medical School, Boston, Massachusetts - 10/11/2012

Other

Authored Content

  • Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018

Press Mentions

  • Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in Practice
    Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
  • POINT Biopharma Global : Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-Α (Rosopatamab-225Ac) in Combination with PNT2002 for Progressive mCRPC
    POINT Biopharma Global : Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-Α (Rosopatamab-225Ac) in Combination with PNT2002 for Progressive mCRPCSeptember 14th, 2021
  • Ziopharm Finds New CEO After Six-Month Search; CFO Transition at Lonza to Take Place in December
    Ziopharm Finds New CEO After Six-Month Search; CFO Transition at Lonza to Take Place in DecemberSeptember 3rd, 2021
  • Join now to see all

Grant Support

  • Df/Hcc Spore In Prostate CancerNational Cancer Institute2007–2011
  • Developmental Research ProgramNational Cancer Institute2007–2011
  • Career Development ProgramNational Cancer Institute2007–2011
  • Administration, Evaluation, And Planning CoreNational Cancer Institute2007–2011
  • Molecular Signatures Of Lethal An Indolent Prostate CancerNational Cancer Institute2007–2009
  • Spore In Prostate CancerNational Cancer Institute2002–2006
  • Developmental Projects ProgramNational Cancer Institute2002

Professional Memberships

Dr. Philip Kantoff, Dr. Philip Kantoff, MD, Dr. P Kantoff, Dr. Philip W Kantoff